Head-To-Head Survey: Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and InspireMD (NYSE:NSPR)

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Earnings & Valuation

This table compares Defiance Daily Target 2X Long LMND ETF and InspireMD”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF	$437.66 million	0.01	$15.17 million	$0.51	25.31
InspireMD	$10.85 million	3.19	-$19.92 million	($0.73)	-1.01

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Comparatively, 34.1% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Defiance Daily Target 2X Long LMND ETF and InspireMD, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Defiance Daily Target 2X Long LMND ETF	0	0	0	0	0.00
InspireMD	0	0	3	0	3.00

InspireMD has a consensus price target of $4.50, indicating a potential upside of 509.76%. Given InspireMD’s stronger consensus rating and higher probable upside, analysts clearly believe InspireMD is more favorable than Defiance Daily Target 2X Long LMND ETF.

Risk & Volatility

Defiance Daily Target 2X Long LMND ETF has a beta of -10.11, indicating that its share price is 1,111% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Profitability

This table compares Defiance Daily Target 2X Long LMND ETF and InspireMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%
InspireMD	-413.96%	-69.42%	-57.68%

Summary

Defiance Daily Target 2X Long LMND ETF beats InspireMD on 8 of the 14 factors compared between the two stocks.

About Defiance Daily Target 2X Long LMND ETF

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.